KIF2A and gastric cancer: In conclusion, KIF2A is highly expressed and its elevated expression associates with larger tumor size, advanced N stage, TNM stage as well as poor survival in GC patients; meanwhile, its knockdown enhances the chemosensitivity to oxaliplatin and capecitabine in GC cell lines.